Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Electronic Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
NCT05722561Phase 2Recruiting
- Sponsor
- NYU Langone Health
- Start
- Aug 2024
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Tobacco Use Disorder (TUD) (2 arms), sponsored by NYU Langone Health. Primary endpoint: Percentage of Participants who Achieve 100% Reduction in Cigarettes Per Day at Day 56. Started Aug 2024; status: recruiting.
02
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT05722561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05722561.